Tonsillitis (disorder)
D0004 Deposit of tonsils, adenoids and additional samples
Year Started: 2009
Children going for adenotonsillectomy, tonsillectomy or adenoidectomy will be approached to donate samples. Additional samples to be collected at this time may include saliva samples, urine samples, a blood sample and a nasal swab
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
There is no associated data for this collection. |
Female
Infant (1 month - 2 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Tissue specimen | Surgical procedure (procedure) | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Female
Adolescent (12 - 18 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Saliva | -60°C to -85°C | N/A | Not applicable | 0 - 10% | |
Tissue specimen | Surgical procedure (procedure) | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Male
Infant (1 month - 2 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Tissue specimen | Surgical procedure (procedure) | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Male
Adolescent (12 - 18 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | N/A | Not applicable | 0 - 10% | |
Tissue specimen | Surgical procedure (procedure) | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Fit and well (finding)
D0008 Multi-centre Study to Evaluate the Safety, Tolerability and Immunogenicity of Baxter H1N1 vaccine and GlaxoSmithKline H1N1 vaccine in children 6 months to 12 years of age
Year Started: 2009
D0008 Multi-centre Study to Evaluate the Safety, Tolerability and Immunogenicity of Baxter H1N1 vaccine and GlaxoSmithKline H1N1 vaccine in children 6 months to 12 years of age
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
There is no associated data for this collection. |
Female
Infant (1 month - 2 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Male
Infant (1 month - 2 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Fit and well (finding)
D0009 Study to evaluate the induction of immune memory following infant vaccination with a glycol-conjugate Neisseria Meningitidis serogroup C Vaccine
Year Started: 2011
Please note, this collection consists of blood clots but it is listed as plasma. Study to evaluate the induction of immune memory following infant vaccination with a glycol-conjugate Neisseria Meningitidis serogroup C Vaccine and to assess the immune response to the concurrent infant routine immunisations administered in consistent versus alternating limbs.
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
There is no associated data for this collection. |
Female
Infant (1 month - 2 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Female
Adolescent (12 - 18 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Male
Infant (1 month - 2 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Male
Adolescent (12 - 18 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
DNA | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Male
Adolescent (12 - 18 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Fit and well (finding)
D0010 Comparison study of two H1N1 influenza vaccines in children
Year Started: 2010
A multi-centre, open-label, clinical, phase 4 trial, following on from a head-to-head comparison study of two H1N1 influenza vaccines in children, to compare firstly, the persistence of antibody against the A/California/7/2009 (H1N1) virus and secondly the immunogenicity and reactogenicity of one dose of a non-adjuvanted trivalent seasonal influenza vaccine, in children who had received a two-dose immunisation regimen of Celvapan or Pandemrix.
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
There is no associated data for this collection. |
Male
Adolescent (12 - 18 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Fit and well (finding)
D0011 Swine Flu (Influenza A H1N1) Follow on Vaccine Study
Year Started: 2010
A multi-centre, open-label, clinical, phase 4 trial, following on from a head-to-head comparison study of two H1N1 influenza vaccines in children, to compare firstly, the persistence of antibody against the A/California/7/2009 (H1N1) virus and secondly the immunogenicity and reactogenicity of one dose of a non-adjuvanted trivalent seasonal influenza vaccine, in children who had received a two-dose immunisation regimen of Celvapan or Pandemrix.
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
There is no associated data for this collection. |
Female
Young child (2 - 6 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Female
Adolescent (12 - 18 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Male
Adolescent (12 - 18 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Fit and well (finding)
D0013 Pilot study to evaluate the kinetics of the systemic B-cell response to a meningococcal serogroup C conjugate vaccine in healthy adults
Year Started: 2006
Meningitis and septicaemia (blood poisoning) caused by the bacterium Neisseria meningitidis (meningococcus) remain important causes of death and disability amongst children and younger adults in the UK and elsewhere. The bacteria can be carried on the mucous membranes in the back of the nose and mouth without causing any symptoms. This so-called carriage state is found in around 10% of the population of the UK at any one time. The bacteria are spread through person to person contact and only occasionally does this spread lead to the development of meningitis and septicaemia rather than carriage. The reasons behind this are not clearly understood. A vaccine against meningococcus group C (Men C), one of five groups of the bacteria that can cause disease, was introduced into the UK in 1999 and led to a sharp drop in the rates of meningitis and septicaemia. The vaccine also led to a decrease in the rates of carriage of the bacteria. This suggests that the vaccine not only generates immune protection preventing meningitis and septicaemia but also generates immunity in the back of the nose and mouth preventing carriage. The way the vaccine generates this “mucosal immunity” is not known and is the topic of our research. This study is the first part of a research programme and aims to identify the way the vaccine works in the blood.
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
There is no associated data for this collection. |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Saliva | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Fit and well (finding)
D0023 Study to demonstrate the efficacy of GlaxoSmithKline Biologicals’ quadrivalent seasonal influenza candidate vaccine GSK2321138A (FLU D-QIV), administered intramuscularly in children 9 to 35 months of age
Year Started: 2011
Please note, this collection consists of blood clots but it is listed as plasma. Study to demonstrate the efficacy of GlaxoSmithKline Biologicals’ quadrivalent seasonal influenza candidate vaccine GSK2321138A (FLU D-QIV), administered intramuscularly in children 9 to 35 months of age.
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
There is no associated data for this collection. |
Female
Infant (1 month - 2 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Plasma | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Fit and well (finding)
D0025 Broader protection against pneumococcal disease: a follow-on study
Year Started: 2010
Please note, this collection consists of blood clots but it is listed as plasma. During the initial study your child received one of 2 pneumococcal vaccines; either the 7-valent pneumococcal vaccine (PCV7) which protects against 7 types of pneumococcal bacteria, or the new 13-valent pneumococcal vaccine (PCV13) protecting against 13 types of pneumococcus which has recently replaced PCV7 in the routine immunisation schedule. The PCV13 vaccine has been shown to produce an immune response against 13 types of pneumococcus and therefore provides a broader level of protection than the PCV7 vaccine. It is now important to determine how well the immune response to the PCV13 vaccine persists throughout childhood. To do this we would like to take a sample of blood from children, who participated in the original study, when they are approximately 3 ½ years of age. We would also like to study the response to a dose of PCV13 vaccine when given to children who were immunised with either PCV7 or PCV13 as an infant.
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
There is no associated data for this collection. |
Female
Young child (2 - 6 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Plasma | -60°C to -85°C | N/A | Not applicable | 26 - 50% |
Fit and well (finding)
D0032 The Bristol Nasal Colonisation Surveillance Study
Year Started: 2011
The effects of viral upper respiratory tract infections on bacterial colonisation of the nasopharynx in young healthy children attending day care centres. A single centre prospective longitudinal follow up study.
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
There is no associated data for this collection. |
Female
Young child (2 - 6 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
RNA | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Male
Infant (1 month - 2 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
RNA | -60°C to -85°C | N/A | Not applicable | 0 - 10% |
Male
Young child (2 - 6 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
RNA | -60°C to -85°C | N/A | Not applicable | 0 - 10% |